Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?

Castañeda-Orjuela, Carlos; García-Molina, Mario; Hoz-Restrepo, Fernando De la

doi:10.1016/j.vhri.2019.09.009

Cited by 4 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature has suggested that the most common economic method used in the economic evaluation of the MD development is the cost-utility analysis [25][26][27][28], followed by the cost-effectiveness analysis [26,29], and the cost-consequence analysis [27,29]. These findings are consistent with other studies on this topic [30,31].…”

Section: Economic Evaluation Methodssupporting

confidence: 84%

Complexity Stage Model of the Medical Device Development Based on Economic Evaluation—MedDee

et al. 2020

View full text Add to dashboard Cite

The development of a new product is essential for the progress and success of any company. The medical device market is very specific, which is challenging. Therefore, this paper assesses an economic model for medical device evaluation using the economic, health, technology regulatory, and present market knowledge to enable the cost–time conception for any applicant. The purpose of this study is to propose a comprehensive stage model of the medical device development to subsequently describe the financial expenditure of the entire development process. The identification of critical steps was based on the literature review, and analysis, and a comparison of the available medical device development stages and directives. Furthermore, a preliminary assessment of the medical device development steps and procedures on the basis of the interviews was performed. Six interviews were conducted with an average duration of one hour, focusing on areas: relevance and level of detail of the medical device development stages, involvement of economic methods, and applicability of the proposed model. Subsequently, the improvement and modification of the medical device investment process, based on respondents’ responses, were conducted. The authors have proposed the complexity model MedDee—Medical Devices Development by Economic Evaluation. This model is comprised of six phases: initiation, concept, design, production, final verification, and market disposition in which the economic methods are incorporated.

show abstract

Section: Economic Evaluation Methodssupporting

confidence: 84%

Complexity Stage Model of the Medical Device Development Based on Economic Evaluation—MedDee

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Foremost in a clinician’s mind is making the best clinical decisions for their patients, and not how those decisions economically affect the wider health system. How the mantra “do no harm” extends from individual patients to the wider health system is a topic of heated debate [ 34 ], as is how cost-effectiveness should be calculated [ 35 ]. However, when two treatments are equally effective clinically but entail different financial costs, then choosing the cheaper treatment should not be controversial.…”

Section: Discussionmentioning

confidence: 99%

Implementation and Evaluation of Two Nudges in a Hospital’s Electronic Prescribing System to Optimise Cost-Effective Prescribing

et al. 2022

View full text Add to dashboard Cite

Providing healthcare workers with cost information about the medications they prescribe can influence their decisions. The current study aimed to analyse the impact of two nudges that presented cost information to prescribers through a hospital’s electronic prescribing system. The nudges were co-created by the research team: four behavioural scientists and the lead hospital pharmacist. The nudges were rolled out sequentially. The first nudge provided simple cost information (percentage cost-difference between two brands of mesalazine: Asacol® and Octasa®). The second nudge provided information about the potential annual cost savings if the cheaper medication were selected across the National Health Service. Neither nudge influenced prescribing. Prescribing of Asacol® and Octasa® at baseline and during the implementation of the first nudge did not differ (at p ≥ 0.05), nor was there a difference between the first nudge and second (at p ≥ 0.05). Although these nudges were not effective, notable administrative barriers were overcome, which may inform future research. For example, although for legal reasons the cost of medicine cannot be displayed, we were able to present aggregated cost information to the prescribers. Future research could reveal more behavioural factors that facilitate medication optimisation.

show abstract

“…DM should include many rationalities from a democratic perspective, where economic evaluation is only one input of all possible. 5 It is necessary to strengthen the process of discussion and not only include a new vaccine in the EPI because it is cost-effective. Initiatives to integrate economic studies into the DM process for the introduction of new and underutilized vaccines as ProVac 10 should not displace other criteria at the time of new vaccine introduction discussion.…”

Section: Discussionmentioning

confidence: 99%

“…Criteria to decide on vaccine introduction may vary significantly across societies and include society specific values and rationalities beyond economic or monetary inputs. 5 Using a previously discussed reference framework for decision making (DM) in public health, we could identify additional inputs such as scientific evidence, equity, ethics, and political priorities. All of them extended the use of cost-effectiveness analysis (CEA) results in a democratic setting where discussion involves different stakeholders and political actors.…”

Section: Introductionmentioning

confidence: 99%

“…All of them extended the use of cost-effectiveness analysis (CEA) results in a democratic setting where discussion involves different stakeholders and political actors. 5 To identify how the decision makers value those different inputs and rationalities is an important research area to fill knowledge gaps about how DM works and could be improved.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Criteria for New Vaccine Introduction in a National Expanded Program on Immunization: A Survey of Expanded Program on Immunization Managers

Castañeda-Orjuela¹,

Hoz-Restrepo²

2022

Value in Health Regional Issues

Self Cite

View full text Add to dashboard Cite

Is There Something Else Beyond Cost-Effectiveness Analysis for Public Health Decision Making?

Cited by 4 publications

References 31 publications

Complexity Stage Model of the Medical Device Development Based on Economic Evaluation—MedDee

Complexity Stage Model of the Medical Device Development Based on Economic Evaluation—MedDee

Implementation and Evaluation of Two Nudges in a Hospital’s Electronic Prescribing System to Optimise Cost-Effective Prescribing

Criteria for New Vaccine Introduction in a National Expanded Program on Immunization: A Survey of Expanded Program on Immunization Managers

Contact Info

Product

Resources

About